相似文献
1
Clinical utility of targeted treatments in the management of epithelial ovarian cancer.
Biologics. 2012;6:233-44. doi: 10.2147/BTT.S29356. Epub 2012 Jul 26.
2
Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer.
Rev Colomb Obstet Ginecol. 2024 Jun 14;75(1):4094. doi: 10.18597/rcog.4094.
3
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
World J Biol Chem. 2010 Jul 26;1(7):209-20. doi: 10.4331/wjbc.v1.i7.209.
4
An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
J Oncol Pharm Pract. 2017 Sep;23(6):454-469. doi: 10.1177/1078155216657165. Epub 2016 Jun 29.
5
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Trials. 2024 May 4;25(1):301. doi: 10.1186/s13063-024-08142-5.
6
Clinical trials and future potential of targeted therapy for ovarian cancer.
Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28.
7
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
8
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3.
9
Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
Curr Pharm Biotechnol. 2018;19(14):1114-1121. doi: 10.2174/1389201020666181226123054.
10
Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.
Curr Treat Options Oncol. 2013 Mar;14(1):22-33. doi: 10.1007/s11864-012-0220-6.
本文引用的文献
1
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23.
2
A phase 3 trial of bevacizumab in ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
3
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.
4
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Oncol. 2012 Feb;13(2):154-62. doi: 10.1016/S1470-2045(11)70338-2. Epub 2011 Dec 20.
5
The role of PARP in DNA repair and its therapeutic exploitation.
Br J Cancer. 2011 Oct 11;105(8):1114-22. doi: 10.1038/bjc.2011.382.
6
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Br J Cancer. 2011 Sep 27;105(7):884-9. doi: 10.1038/bjc.2011.334. Epub 2011 Aug 30.
7
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12.
8
A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study.
Gynecol Oncol. 2011 Jul;122(1):89-94. doi: 10.1016/j.ygyno.2011.03.013. Epub 2011 May 6.
9
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.
10
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
J Clin Oncol. 2011 Apr 1;29(10):1247-51. doi: 10.1200/JCO.2010.32.1075. Epub 2011 Mar 7.
Zotero 插件